While the identification of additional patients with variants in SMAD3 would be required to promote its current Amber PanelApp status, the two variants in SOX6 provide a significant uplift (40%) to the total number of patients currently described in the literature with craniosynostosis and contribute positively to promoting this gene to Green (Table 2). Here, SMAD3 is linked to craniosynostosis.